Prot #M23-647: First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants with B-cell Malignancies

Project: Research project

Project Details

StatusActive
Effective start/end date5/28/24 → 5/28/27

Funding

  • Quintiles, Inc. (Prot #M23-647 AMD 2 // Prot #M23-647 AMD 2)
  • AbbVie Inc. (Prot #M23-647 AMD 2 // Prot #M23-647 AMD 2)